Participated · Series A · May 2026

Shizen Connect builds and operates a VPP energy management system that integrates batteries, EVs, heat pumps (eco-cute) and other devices using IoT and AI to enable aggregated control and market transactions. The company develops its own IoT devices, AI-based optimization, and a digital platform for large-scale VPP and DR services, and sells related hardware. Its platform has been adopted by major utilities and energy companies (including Tokyo Gas, Tokyo Electric Power Energy Partner, Hokkaido Electric Power, Hokuriku Electric Power, Osaka Gas, JERA, Tokyu Fudosan and others) across household DR and grid-scale battery control. Independent market research (Fuji Keizai) cited Shizen Connect as No.1 by corporate contract count in DR/VPP platforms and No.1 in AC/RA system corporate contract counts. The company aims to scale via capital-business alliances with 16 partners to become the de facto standard VPP platform. Shizen Connect was founded on October 2, 2023 and is headquartered in Tokyo; it plans to use newly raised funds to hire engineers and invest further in R&D.

Led · Series B · Oct 2025

Neautech is a 2022-founded Japanese beauty-healthcare startup that develops and runs ANS., an online skin-care management platform. Through a smartphone consultation, users receive physician-prescribed medicines, cosmetics and supplements that are shipped to their homes each month, while ongoing questions are handled through expert chat support. The company blends "human touch" care teams with AI-driven "tech touch" tools, and plans to further embed generative AI and image-based diagnostics to boost treatment adherence and lower churn. Its member base has surpassed 260,000 users and gross merchandise value grew more than 300 % year-on-year between July 2024 and July 2025. Proceeds from the latest financing will be directed toward upgrading the combined human-and-tech support system, expanding physician and customer-success staffing, and strengthening branding. Neautech ultimately aims to extend its "continue-able" treatment model beyond dermatology to additional medical fields.

Participated · Equity · Jul 2024

KINS is a microbiome-focused healthcare company that researches, develops, and sells products based on proprietary bacteria, including recently acquired polyamine-producing lactic acid strains. Its core offerings span consumer products (20+ SKUs) and clinic services, supported by a proprietary bacterial bank of over ~20,000 human skin specimens. The firm reports more than 100,000 cumulative users and operates two animal hospitals in Japan and one human clinic in Singapore. KINS is advancing R&D into microbiome drug seeds while preparing probiotic products and bacterial raw materials for commercial sale. The company is investing in research capability (hiring, lab expansion, equipment), PR and organizational buildout to commercialize its bacteria across B2C and B2B channels. It also plans to strengthen consumer sales via its own e-commerce and marketplace channels and to pursue joint-development and distribution partnerships with strategic corporate partners.

Participated · Series B · Jun 2024

Battery Smart operates a battery-as-a-service platform that lets EV drivers swap depleted batteries for charged units in minutes, reducing vehicle downtime and upfront costs. The company serves primarily last-mile delivery and passenger mobility segments and partners with local operators to run its stations. It currently runs more than 1,600 partner-led stations across 50 cities. Battery Smart plans to expand its BaaS infrastructure and network of partner stations, with the recent debt funding intended to accelerate that roll-out and improve access for gig workers and fleet operators. The startup has raised about $192 million to date, including a $65 million Series B and a $29 million extended Series B. Financially, the company reported a 52% year-on-year increase in operating revenue to Rs 249 crore in FY25 and stated it has reached operating break-even and become EBITDA positive.

Participated · Equity · Mar 2024

Zene offers Zene360, a healthcare service that uses genome analysis to predict individual health risks and disease tendencies and to deliver concrete action plans. Users collect saliva with a provided kit and return it for analysis; when risks are identified Zene supplies individualized health measures. Zene360 is commercially deployed as a paid service to more than 200 health-insurance societies and other corporate clients. The company did not disclose the newest round size, but reports cumulative funding including debt of about ¥401 million. The latest round included participation from Spiral Capital and Panasonic's Kurashi Visionary Fund (Panasonic's CVC). Zene plans to expand partnerships, link Zene360 with specific health guidance programs, and develop a new integrated platform leveraging genomic information while strengthening information-management and customer-data privacy protections.